ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer

Friday, April 10, 2020

Submitted by

Emily Robinson

Source

Source Name: The Annals of Thoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2019.09.076

Author(s)

Jonathan D. Rice, Justin Heidel, Jaimin R. Trivedi, Victor H. van Berkel

The NCDB was queried to assess the optimal timing for resection after induction therapy for IIIA NSCLC. Survival was better in patients who underwent surgery in a short delay interval (<77 days) compared to a long delay (>114 days); short and medium delay intervals had similar outcomes.